Trials / Active Not Recruiting
Active Not RecruitingNCT04524208
A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3
CABONEN - A Phase II Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- Karsten Gavenis · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of this clinical trial represents the evaluation of efficacy of the tyrosine kinase inhibitor Cabozantinib in patients with NEN G3 with a proliferation rate of Ki67 20 - 60%.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cabozantinib | Cabozantinib is administered orally at the dose of 60 mg per day.. |
Timeline
- Start date
- 2021-03-01
- Primary completion
- 2024-09-30
- Completion
- 2024-10-31
- First posted
- 2020-08-24
- Last updated
- 2024-08-13
Locations
15 sites across 2 countries: Austria, Germany
Source: ClinicalTrials.gov record NCT04524208. Inclusion in this directory is not an endorsement.